The Predictive Role of Urinary Proteomics in Blood Pressure Response of Obese Hypertensive Treated With Irbesartan or Eplerenone.
Condition(s):Primary Hypertension; ObesityLast Updated:January 17, 2024Recruiting
Include Studies Not Open or Pending
Condition(s):Primary Hypertension; ObesityLast Updated:January 17, 2024Recruiting
Condition(s):Obesity, MorbidLast Updated:April 13, 2023Recruiting
Condition(s):Acute Kidney InjuryLast Updated:January 12, 2024Recruiting
Condition(s):ANCA Associated Vasculitis; Cardiovascular Diseases; Kidney DiseasesLast Updated:January 27, 2023Recruiting
Condition(s):Diabetic NephropathyLast Updated:July 3, 2023Recruiting
Condition(s):Chronic Kidney Diseases; Hyperkalemia; HypertensionLast Updated:February 23, 2024Not yet recruiting
Condition(s):Sacubitril/Valsartan; Hypertension; ObesityLast Updated:August 8, 2023Recruiting
Condition(s):Ischemic Stroke; Revascularization; Blood Pressure; Cerebrovascular Insufficiency; Cerebral Autoregulation; Individuation; Hemorrhagic Transformation Due to Acute StrokeLast Updated:January 5, 2023Not yet recruiting
Condition(s):Heart Diseases; Diabetes Mellitus, Type 2Last Updated:March 14, 2023Recruiting
Condition(s):Community-acquired Pneumonia, Influenza, COVID-19Last Updated:February 28, 2024Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.